Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome

Harinath Sale,* Jinling Wang,* Thomas J. O’Hara,* David J. Tester, Pallavi Phartiyal, Jia-Qiang He, Yoram Rudy, Michael J. Ackerman, Gail A. Robertson

Abstract—Cardiac $I_{Kr}$ is a critical repolarizing current in the heart and a target for inherited and acquired long-QT syndrome (LQTS). Biochemical and functional studies have demonstrated that $I_{Kr}$ channels are heteromers composed of both hERG 1a and 1b subunits, yet our current understanding of $I_{Kr}$ functional properties derives primarily from studies of homooligomers of the original hERG 1a isolate. Here, we examine currents produced by hERG 1a and 1a/1b channels expressed in HEK-293 cells at near-physiological temperatures. We find that heteromeric hERG 1a/1b currents are much larger than hERG 1a currents and conduct 80% more charge during an action potential. This surprising difference corresponds to a 2-fold increase in the apparent rates of activation and recovery from inactivation, thus reducing rectification and facilitating current rebound during repolarization. Kinetic modeling shows these gating differences account quantitatively for the differences in current amplitude between the 2 channel types. Drug sensitivity was also different. Compared to homomeric 1a channels, heteromeric 1a/1b channels were inhibited by E-4031 with a slower time course and a corresponding 4-fold shift in the IC$_{50}$. The importance of hERG 1b in vivo is supported by the identification of a 1b-specific A8V missense mutation in 1/269 unrelated genotype-negative LQTS patients that was absent in 400 control alleles. Mutant 1bA8V expressed alone or with hERG 1a in HEK-293 cells dramatically reduced 1b protein levels. Thus, mutations specifically disrupting hERG 1b function are expected to reduce cardiac $I_{Kr}$ and enhance drug sensitivity, and represent a potential mechanism underlying inherited or acquired LQTS. (Circ Res. 2008;103:e81-e95.)

Key Words: Kv11.1 ■ KCNH2 ■ ether-à-go-go ■ arrhythmia ■ potassium channels

Cardiac $I_{Kr}$ is a potassium current contributing to ventricular repolarization in mammalian heart.1,2 The molecular basis of cardiac $I_{Kr}$ was first elucidated when its unique biophysical and pharmacological properties were largely reproduced by heterologous expression of the hERG1 gene (human ether-à-go-go-related gene) (or KCNH2).3,4 Together with the discovery of KCNH2 mutations as the pathogenic substrate in families with type 2 long-QT syndrome (LQTS),3,4 these studies explained the underlying cause of disease as a loss of cardiac $I_{Kr}$. They also identified hERG 1 channels as a molecular target for acquired LQTS, a much more prevalent form of the disease arising from $I_{Kr}$ block primarily by drugs intended for other therapeutic targets.6 In either manifestation, LQTS is characterized by prolonged ventricular action potentials and a susceptibility to potentially life-threatening arrhythmias known as torsades de pointes (TdP).7

Our understanding of how $I_{Kr}$ contributes to ventricular repolarization is based primarily on heterologous expression of the originally identified hERG 1a subunit.3,4,8,9 Like other voltage-gated potassium channels, hERG 1a channels activate and inactivate on depolarization. However, because inactivation is much faster than activation, current is suppressed at positive potentials but rebounds on repolarization as channels quickly recover from inactivation and slowly close. During an action potential, these gating transitions produce a resurgent current that peaks during the repolarizing phase.10 Gating is modulated by the cytoplasmic amino (N) terminus, with different regions affecting deactivation, inactivation, and activation.11–15

More recent studies suggest that native $I_{Kr}$ channels are heteromers arising from coassembly of hERG 1a with 1b, another $\alpha$ subunit encoded by an alternate transcript of KCNH2. The 2 transcripts, first characterized in mouse and human, are identical except for alternate 5' exons encoding unique cytoplasmic N termini of significantly different sizes (Figure 1A).16,17 Expressed in heterologous systems, the 1a
and 1b subunits coassemble to form functional channels, a process that is facilitated by direct, cotranslational interactions of the divergent N termini. Such interactions mask an exposed endoplasmic reticulum retention signal (RXR) in the 1b subunit, which otherwise prevents efficient expression of hERG 1b homomeric channels. Isoform-specific antibodies can coimmunoprecipitate 1a and 1b subunits from rat, canine, and human ventricle, suggesting that both proteins indeed associate to form native I\textsubscript{Kr} channels. In addition, both isoforms show extensive T-tubular distribution in canine myocytes. In a selective knockout of mouse ERG1b, fetal I\textsubscript{Kr} deactivation rate is decreased, and a small dofetilide-sensitive component of outward current in adult cardiomyocytes is eliminated. Despite the evidence that heteromeric hERG 1a/1b channels underlie cardiac I\textsubscript{Kr}, we know little about the gating and pharmacological properties of these channels, how hERG 1a/1b channels differ from hERG 1a homomers, or what role the hERG 1b subunit might play in disease. Here, we describe for the first time the biophysical properties of hERG 1a/1b heteromeric channels at near-physiological temperatures in mammalian cells. We find that hERG 1a/1b currents are significantly larger than hERG 1a currents because of an increased activation rate and a faster rate of recovery from inactivation. In addition, hERG 1a/1b currents peak earlier than 1a currents during the action potential. Despite their increased occupancy of the open state, hERG 1a/1b channels develop E-4031 block with slower kinetics and a 4-fold...

Figure 1. Greater amplitude currents for hERG 1a/1b compared to hERG 1a channels. A, Graphic showing N-terminal differences in primary structure between hERG 1a (upper) and hERG 1b (lower). Cytoplasmic N and C termini flank the hydrophobic core. N-terminal differences yield subunits of 1159- and 819-aa residues for hERG 1a and 1b, respectively. PAS indicates Per–Arnt–Sim domain; PAC, PAS-associated C-terminal domain; CNBD, putative cyclic nucleotide binding domain; TCC, tetramerization coiled-coil domain. B, Currents from stably transfected hERG 1a cells (upper) or hERG 1a stable cells transiently transfected with hERG 1b (lower). All currents were recorded at 34 ± 2°C in response to a series of 4-second depolarizing voltage steps ranging from −120 to 60 mV, followed by a 5-second repolarizing step to −50 mV. C, Steady-state I-V relations of hERG 1a and hERG 1a/1b channels, both displaying the hallmark negative slope conductance (n = 5 to 6 for both). The currents at the end of each depolarizing pulse were normalized to the absolute value of the extrapolated maximum tail current and plotted as a function of membrane potential. D, Double exponential fits (in red) of tail currents evoked following a step to 60 mV extrapolated back to the moment of voltage change to obtain peak current value (I\textsubscript{max}) (see Materials and Methods).
reduced sensitivity compared with hERG 1a channels, suggesting that a loss of the 1b subunit would enhance drug sensitivity and susceptibility to acquired LQTS. Kinetic modeling can account for these differences by introducing “N-mode” gating with alternative transition rates. A role for hERG 1b in LQTS is further supported by the identification of a 1b-specific mutation in a patient with clinically diagnosed LQTS who had remained genotype negative for all known LQTS-susceptibility genes.

**Materials and Methods**

**Cell Culture**

hERG 1a currents were recorded from a stable hERG 1a/HEK-293 cell line. The cells were maintained and passaged using minimum essential medium supplemented with 10% FBS, 1% nonessential amino acids, 1% sodium pyruvate, and 400 μg/mL geneticin (Invitrogen). For recordings of heteromeric 1a/1b channels, 2 μg of hERG 1b cdNA was transiently transfected into a stable hERG 1a cell line along with EGFP cDNA, leading to an average ratio of 1a:1b expression of 1:2. Cells were incubated for 36 to 48 hours before recording. In preparation for electrophysiological recording, cells were trypsinized, washed in standard MEM media, and plated onto cover slips on the day of recording. After a few hours, the cover slip was placed in a recording chamber on a Nikon Diaphot inverted microscope. Cells with green fluorescence were chosen for 1a/1b recordings.

**Electrophysiological Procedures and Analysis**

Whole-cell patch-clamp recordings were performed using an Axopatch 200B amplifier (Axon Instruments Inc). PClamp software (Axon Instruments) was used for data acquisition and analysis. The recording chamber was perfused with Heps-buffered Tyrode solution containing (in mmol/L) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 glucose, and 10 Heps (pH 7.4 with NaOH). Whole-cell currents were recorded with a fire-polished pipette tip of approximately 1 to 2 μm with a resistance of 2 to 4 MΩ when filled with the internal pipette solution. Internal pipette solution contained (in mmol/L) 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, and 10 Heps (pH 7.2 with KOH). Currents were digitized at 1 to 20 kHz unfiltered. Series resistance compensation was typically 60% to 70%, such that voltage errors were less than 5 mV. No leak subtraction was applied; cells exhibiting leak conductance >10% maximal conductance were excluded from the study. Temperature was regulated by an in-line solution heater made locally. All experiments reported here were carried out at 34±2°C to approximate physiological conditions, except for the pharmacologic experiments, which were carried out at room temperature (22±2°C) because at higher temperatures, the seals were insufficiently stable to endure the long recordings required for measuring drug sensitivity.

Experiments were carried out using both voltage step and simulated action potential protocols to better mimic the native electrical signals in cardiac myocytes. The action potential voltage command was the same as that used previously, a digitized recording from a rabbit ventricular myocyte. Differences in rectification between hERG 1a and 1a/1b channels were revealed in current–voltage (I–V) plots from currents elicited using both voltage clamp protocols (Figures 1C and 2B, respectively) and divided by the absolute value of the maximum peak deactivating inward tail current evoked subsequent to a pulse to +60 mV. The peak current, determined using a 2-exponential fit to the deactivating current extrapolated back to the moment of the voltage change (Figure 1D), represents the maximal conductance and is proportional to the number of channels in the cell. This approach requires single channel conductance to be the same for hERG 1a and 1a/1b channels, a reasonable assumption for 2 channel types identical except for their cytoplasmic N termini; moreover, we know from previous work that removal of the hERG 1a N terminus does not alter single channel conductance. In this way, the degree of rectification could be characterized for hERG 1a versus 1a/1b channels, irrespective of differences in transfection efficiency or the corresponding number of channels expressed in each cell, which would otherwise prohibit comparison.

Steady-state inactivation was measured as previously published but with shorter test potentials to minimize the contamination by the faster deactivation at the higher temperatures used in our study. Errors attributable to deactivation were corrected for and the resulting normalized currents plotted versus test voltage and fit with a Boltzmann function. The short pulse causes a positive shift of the $V_{1/2}$ of the resulting steady-state inactivation curve from what might be considered “true” steady state. Therefore, actual $V_{1/2}$ values differ based on the method used and at different temperatures, but the observed shift in $V_{1/2}$ between hERG 1a and 1a/1b channels can provide information about how gating differences result in an alteration of the distribution between the inactivated and activated states.

For drug block measurements, current was activated by a 4-second long depolarizing pulse to 20 mV from a holding potential of −80 mV, and the peak tail current was recorded at −50 mV. After control currents were recorded, E-4031 (Sigma) was perfused for 2 minutes and then incubated for 10 minutes while the cell was held at −80 mV to maintain the channels in a closed state. Following the 10 minutes of incubation, depolarizing steps were applied for 20 times at 15-second interpulse intervals until steady-state block was reached.

GraphPad Prism (GraphPad Software Inc) and pClamp were used to analyze data and generate statistical plots. Curves were fit using nonlinear least-squares regression analysis. Conductance and voltage data were fitted to a single Boltzmann function: $I_{\text{max}}(I_{\text{max}}-I_{\text{off}}[1+exp(-(V_{1/2}-V)/n)])$, where, $V_{1/2}$ is the half-activation potential, $V$ is the test voltage, and $n$ is the slope factor. The relative charge transfer through 1a/1b and 1a channels was determined by integrating the normalized current traces (area under the curve). $IC_{50}$ SEM values were obtained from best-fit results using the following sigmoidal concentration–response function: $I/I_{\text{max}}(1+[IC_{50}/X])$, where $I$ denotes relative tail current, $I_{\text{max}}$ is the peak tail current, $X$ is the concentration of test compound in log scale, $n$ is the Hill coefficient reflecting the number of drug binding sites, and $IC_{50}$ is the concentration at 50% of maximal inhibition. Averaged data are presented as the means±SEM. Statistical comparisons were made using the Mann–Whitney test. Probability values of <0.05 were considered statistically significant.

**Computational Modeling**

Detailed computational modeling methods and model equations are provided in the expanded Materials and Methods section of the online data supplement.

**KCNH2 Exon 1b Mutational Analysis**

Previously, a comprehensive mutational analysis of all 60-aa-encoding exons of the 5 cardiac channel LQTS-associated genes was completed for 541 consecutive, unrelated patients (358 females; average age at diagnosis, 24±16 years; average QTc, 482±57 ms) who were referred to the Windland Smith Rice Sudden Death Genomics Laboratory at Mayo Clinic for LQTS genetic testing between August 1997 and July 2004. This study focused on the 269 unrelated patients in whom no LQTS-associated mutations were identified following this analysis. This cohort is referred to as "genotype-negative" LQTS. Samples were collected in accordance with protocols approved by the Mayo Clinic.

Genomic DNA panels derived from 100 healthy white and 100 black subjects was obtained from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriel.org/ninds) and served as controls.

Mutational analysis of KCNH2 exon 1b was performed using PCR, denaturing high-performance liquid chromatography, and direct DNA sequencing as previously described. This alternate exon was not included in the original analysis and KCNH2 exon 1b is not presently included as part of the clinically available genetic test for LQTS. Previously published PCR primers and reaction conditions were used in this study.
Mutagenesis and Western Blot Analysis

The A8V mutation was introduced into the hERG 1b construct using a PCR-based mutagenesis strategy; sequence analysis confirmed the presence of the mutation and integrity of all other sequence. To generate Western blots, HEK-293 cells were transfected with 1.5 μg of each DNA construct using LT1 reagent (Mirus, Madison, Wis). Cells were lysed 48 hours posttransfection and processed as described previously.18 Cell lysate (5 to 10 μg) was separated by SDS-PAGE, transferred to Immobilon-P poly(vinylidene difluoride) membranes (Millipore, Bedford, Mass), and probed with antibodies raised against the C terminus of hERG.26 Membranes were also probed with anti-PDI as a loading control. Standard Western blot procedures were followed for detection of protein signal on X-ray film.

Results

Differences in Steady-State I-V Relations

As a first step in characterizing differences in hERG 1a and 1a/1b channels, we recorded whole-cell currents using patch clamp at 34 ± 2°C from HEK-293 cells heterologously expressing the corresponding cDNA (Figure 1). Currents were activated by 4-second step commands in 20-mV increments over a range of voltages from −120 mV to 60 mV from a holding potential of −80 mV (Figure 1B). Tail currents were evoked by a subsequent step to −105 mV. Expression of 1b alone in HEK-293 cells, like Xenopus oocytes,17 produced little or no current (data not shown). The currents at the end of each pulse were normalized to the absolute value of the extrapolated maximum tail current obtained for each cell following the step to +60 mV and plotted versus voltage (Figure 1C and 1D; see Materials and Methods). This analysis shows that although both 1a and 1a/1b currents display the hallmark negative-slope conductance characteristic of hERG I-V relations, hERG 1a/1b currents are much larger and exhibit less rectification.

Currents Are Larger and Peak Earlier During the Action Potential for hERG 1a/1b Versus hERG 1a Channels

To understand the physiological ramifications of hERG 1a/1b heteromerization, we evoked currents using voltage clamp commands mimicking ventricular action potentials at 34 ± 2°C (Figure 2). Normalizing the current evoked using the action potential clamp to the extrapolated peak tail current elicited following a step command in the same cell (see Materials and Methods) shows the resulting 1a/1b currents...
were larger and peaked earlier during the action potential (Figure 2A). A “dynamic I-V” plot shows normalized currents sampled at 1-ms intervals and averaged over several experiments as a function of the action potential voltage (Figure 2B). This data transformation highlights the greater amplitude and shift in peak current of 1a/1b relative to 1a. Integrating the normalized current traces indicated hERG 1a/1b currents transfer 80% more charge during the action potential voltage command (Figure 2C).

Differences in Activation and Deactivation
To determine the biophysical basis for the reduced rectification of hERG 1a/1b current, we examined gating properties using a variety of paradigms. The steady-state activation curve representing the distribution between the closed and open states over a range of voltages showed no significant shift in voltage of half-maximal activation or slope factor (Figure 3A). For 1a channels, \( V_{1/2} \) and the slope factor are \(-26.8\pm1.3 \text{ mV} \) and \( 6.9\pm0.2 \), respectively \((n=6)\); for 1a/1b channels, \(-28.6\pm1.0 \text{ mV} \) and \( 6.2\pm0.1 \), respectively \((n=5); P>0.05\), Mann–Whitney test). B, Currents evoked using an envelope of tails protocol to determine time course of activation. Peak inward tail currents were evoked by a step to \(-105 \text{ mV} \) following a prepulse of increasing duration to 0 mV. Holding potential was \(-80 \text{ mV} \). C, Apparent activation is faster for hERG 1a/1b compared with hERG 1a currents. The peak amplitudes of the tail currents (B) were plotted against test pulse duration and fit to single exponential function. Time constants of activation were \( 98.7\pm17.6 \text{ ms} \) and \( 41.6\pm6.7 \text{ ms} \) for hERG 1a and 1a/1b, respectively. Each point is the mean\(\pm\)SEM of 4 to 6 cells. D, Deactivation is faster for hERG 1a/1b vs hERG 1a currents. Scaled tail currents recorded at \(-105 \text{ mV} \) are shown. E and F, Time constants of fast and slow components from double exponential fits to deactivating tail currents are plotted for comparison between 1a and 1a/1b channels. \(*P<0.05\) (Mann–Whitney test). Temperature is 34\(\pm2^\circ\text{C}\).
step to 0 mV, is plotted as a function of time in Figure 3C. Pooled data over several experiments were fit with a single exponential function as shown. This analysis reveals a time constant of activation of $98.7 \pm 17.6$ ms ($n=6$) for hERG 1a and $41.6 \pm 6.7$ ms ($n=4$) for hERG 1a/1b, reflecting an approximately 2-fold increase in the apparent rate of transition from the closed to the open state for the heteromeric channels.

We determined deactivation kinetics from tail currents evoked at $-105$ mV subsequent to a step to 60 mV (Figure 3D). Fitting the deactivating component of the tail current with the double exponential function $y=A_e+A_f e^{-v t}+A_s e^{-v t}$ revealed fast and slow time constants ($\tau$) (Figure 3E and 3F, respectively). The fast time constants, which account for $\approx90\%$ of the deactivating component at $-105$ mV for hERG 1a and 1a/1b, are $12.4 \pm 0.9$ ms ($n=5$) and $5.5 \pm 0.4$ ms ($n=6$), respectively, reflecting a nearly 2-fold difference in apparent closing rate (Figure 3E) ($P<0.05$). The time constants of the slow deactivation component for 1a versus 1a/1b were not significantly different ($P>0.05$) (Figure 3F).

Differences in Inactivation and Recovery From Inactivation

Previous studies have shown that rectification of hERG 1a currents arises because inactivation is much faster than activation, thus minimizing the dwell time in the open state and effectively suppressing outward current in response to positive voltage commands. We tested the hypothesis that differences in inactivation contribute to the reduced rectification of hERG 1a/1b channels. Using the “3-pulse” protocol that separates inactivation from the temporally overlapping activation process (Figure 4A), we were surprised to find no differences in the time constant of inactivation ($P>0.05$) (Figure 4B). Instead, there was approximately a 2-fold difference in the time constant of recovery from inactivation ($P<0.05$) (Figure 4C and 4D), consistent with the earlier trajectory of resurgent current and larger current amplitude. There is a corresponding 28-mV shift in the steady-state inactivation curve, with average $V_{1/2}$ values of $-14.5$ and $13.68$ mV for hERG 1a and hERG 1a/1b, respectively (Figure 4E).

Comparison of E-4031 Block of hERG 1a and -1a/1b Channels

Although hERG 1a/1b and hERG 1a channel pores share the same primary structure, and thus likely the same drug binding sites, we tested the hypothesis that differences in gating kinetics might cause access-related differences in the efficacy of block. Specifically, we predicted the increased open time accounting for larger current amplitudes would enhance drug block in hERG 1a/1b channels. We examined steady-state block by the methanesulfonanilide hERG blocker E-4031 at room temperature. The resulting dose–response curve shows an increase in the IC$_{50}$ for E-4031 inhibition of hERG 1a/1b versus 1a currents, from $6.2 \pm 1.1$ to $25.6 \pm 4.3$ mmol/L, respectively (Figure 5A). A corresponding slowing of block was observed (Figure 5B). This reduction in efficacy for hERG 1a/1b channels, although modest, was nonetheless surprising given that E-4031 is an open-channel blocker and 1a/1b channels spend more time in the open state than do 1a channels.

A Kinetic Model Explains Increased Current Amplitude and Decreased Drug Sensitivity of hERG 1a/1b Channels

We turned to kinetic modeling to determine whether the faster apparent rates of activation and recovery from inactivation could quantitatively account for the increased current amplitude of hERG 1a/1b channels. To be valid, the model also had to explain the paradoxical reduction in efficacy of drug block. We arrived at our designs for Markov models of hERG 1a/1b and hERG 1a by considering how the known protein structural differences might account for the measured biophysical differences in the currents. Given that hERG 1a is structurally identical to hERG 1b with the exception of its longer and unique N terminus, we propose that the presence of the extended N termini on all 4 subunits in the hERG 1a channel causes an interaction that introduces an alternative gating mode (“N-mode”) not in effect for hERG 1a/1b channels where the extended N termini are present in 3 or fewer subunits.

Figure 6 illustrates the state diagrams for hERG 1a/1b and hERG 1a models. In the absence of the hERG blocking drug E-4031, the model for hERG 1a/1b (blue) includes 5 states connected as in Silva and Rudy27 ($c_3$, $c_2$, $c_1$, $o$, and $i$). The model for hERG 1a (red) includes a normal mode of gating with states and transitions identical to hERG 1a/1b. When E-4031 is present, the transition rate ON becomes nonzero, allowing movement from $o$ to the E-4031 block mode (green rectangle) in both hERG 1a/1b and hERG 1a models. We allow gating to occur while the drug remains trapped in the pore.28–30 The hERG 1a model also includes N-mode gating reflecting the action of the N termini in the hERG 1a homomer previously shown to affect gating12–15 (turquoise rectangle). N-mode access is via the open state along $\theta/p$ transition rates. N-mode transition rates are altered as described in the upper right corner of the figure. hERG 1a has 2 equally conducting open states ($o$ and $on$, circled in black). hERG 1a/1b has 1 conducting open state ($o$, circled in black).

For hERG 1a, E-4031 block and N-mode gating may exist in isolation or they may overlap (N-mode plus E-4031 block mode, intersection of green and turquoise rectangles). E-4031 block and N-mode gating are separate and independent processes, but they may occur simultaneously (eg, along transition path $\kappa$). This is achieved by imposing that $\kappa$, $\nu$, $\lambda$, and $\delta$ transitions comply with microscopic reversibility. Moreover, simultaneity follows as a natural consequence of our inclusion of the combination N-mode gating together with E-4031 block, which implies nonexclusionary binding of the 1a N termini and E-4031.

For model validation, we show simulated reproductions of important experimental results for hERG 1a/1b and hERG 1a in Figures 7 and 8. We assume that maximum single channel conductance is the same for hERG 1a/1b and hERG 1a, so all differences are attributed to channel kinetic properties. The simulations show general agreement with the experimental observations with respect to normalized steady-state I-V relations (Figure 7A), steady-state conductance–voltage rela-
tions (Figure 7B), and rates of inactivation and recovery from inactivation (Figure 7C and 7D). The time constant for activation and the fast time constant for deactivation were matched by the models (hERG 1a/1b activation [ms]: experiment/H11005 41.6/H11006 6.7, model/H11005 40.9; hERG 1a activation [ms]: experiment/H11005 98.7/H11006 17.6, model/H11005 107.1; hERG 1a/1b fast deactivation [ms]: experiment/H11005 5.5/H11006 0.4, model/H11005 5.8; hERG 1a fast deactivation [ms]: experiment/H11005 12.4±0.9, model/H11005 11.0). Thus, the observed alterations in kinetics can quantitatively account for the decrease in rectification and concomitant increase in current amplitude during step or action potential voltage commands (Figures 7A and 8A, respectively), as well as the increased charge transferred during repolarization (Figure 8B). The faster rate of deactivation in hERG 1a/1b contributes to the earlier peak and to lower amplitude currents but only at more negative voltages. Notably, simulations show E-4031 sensitivity is greater for hERG 1a than hERG 1a/1b, as observed experimentally (Figure 8C). Also, as observed in the experiments, simulations demonstrate faster block for hERG 1a than for hERG 1a/1b (ie, maximal degree of block is reached in fewer cycles of the protocol; data not shown).

The model provides some insights into the paradox of why E-4031, a use-dependent channel blocker,28,31–34 is more efficacious in blocking hERG 1a channels, which we show spend less time in the open state than do hERG 1a/1b
channels. Although drug binding/unbinding rates (ON/OFF) in the hERG 1a/1b and hERG 1a models are identical, additional E-4031 blocked states are afforded by the combination N-mode plus E-4031 block mode for hERG 1a channels. This allows for more complete block. Furthermore, blocked states are accessible via additional pathways (ie, α and λ). This allows for more rapid block development. Thus, openings, although not as frequent because of different channel kinetics, lead to more complete and rapid E-4031 block for hERG 1a than for hERG 1a/1b, even when the same ON/OFF rates are used for both.

Loss of hERG 1b Prolongs Action Potential Duration and Enhances E-4031 Sensitivity in Myocyte Models

Effects on action potential duration (APD) of hERG 1a/1b (blue) and hERG 1a (red) substituted for the native If in the human-based Fink modified35 ten Tusscher action potential model36 are shown in Figure 9A. APD₉₀ (time between activation and 90% repolarization) for hERG 1a is 376 ms. This is 38 ms longer than APD₉₀ for hERG 1a/1b. The hERG 1a versus hERG 1a/1b prolongation is 30 ms when our models are incorporated into the Priebe and Beuckelmann action potential model37 (data not shown). Prolongation occurs because N-mode occupancy results in slower activation, and slower closed-state inactivation, effects that are explained in detail in Figure I of the online data supplement. In the presence of E-4031, APD₉₀ increases for both hERG 1a/1b and hERG 1a (Figure 9B). Interestingly, ΔAPD₉₀ (defined as APD₉₀ for hERG 1a minus APD₉₀ for hERG 1a/1b) also increases with increasing [E-4031] (Figure 9C). At 10 nmol/L E-4031, the hERG 1a action potential achieves full repolarization on the odd beats (eg, 999th beat, shown), but fails to do so on the even beats (eg, 1000th beat). The alternating pattern for hERG 1a is a consequence of sustained depolarization curtailting deactivation at the end of even beats. This provides immediately available hERG current at the start of odd beats, without the usual delay of slow N-mode activation (channels are still open at t=0, s + on=0.1). For [E-4031]=30 nmol/L, both hERG 1a and hERG 1a/1b action potentials fail to repolarize during the pacing cycle length (data not shown). Similar results were found using our hERG models and following the same protocol in the Priebe and Beuckelmann action potential model37 (data not shown). Specifically, with increasing doses of E-4031, APD₉₀ becomes longer for both hERG 1a/1b and hERG 1a. Also, ΔAPD₉₀ between hERG 1a and hERG 1a/1b increases with increasing E-4031 concentrations ([E-4031]=0 nmol/L, ΔAPD₉₀=30 ms; [E-4031]=5 nmol/L, ΔAPD₉₀=258 ms; [E-4031]=10 nmol/L, ΔAPD₉₀=1187 ms). Using Priebe and Beuckelmann, both hERG 1a/1b and hERG 1a action potentials fail to repolarize during the pacing cycle length for [E-4031]=30 nmol/L. In supplemental Figure II, we use the Luo–Rudy model38 to demonstrate that pause-induced early afterdepolarizations are evoked selectively for hERG 1a. Taken together with the fact that excessive APD prolongation can cause arrhythmia, these results suggest that hERG blocking drugs are more arrhythmogenic for hERG 1a than they are for hERG 1a/1b.

Identification of a hERG 1b-Specific Mutation in a Patient With LQTS

Seeking evidence for the importance of hERG 1b in vivo, we performed mutational analysis of the hERG 1b-specific alternate exon (ie, KCNH2 exon 1b) in 269 unrelated LQTS referral patients who remained genotype-negative following a comprehensive mutational analysis of the LQTS genes KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2. This analysis revealed an alanine-to-valine substitution at amino acid position 8 of the hERG 1b N terminus (p. A8V, c. 23C>T) in an 8-year-old white female who had experienced exercise-induced cardiac arrest and demonstrated on serial electrocardiograms a QTc ranging from 450 to 480 ms (Figure 10). This nonsynonymous variant was absent in 400 references alleles (100 whites and 100 blacks) and represents the first report of a potential hERG 1b-specific disease mutation.

Western blot analysis showed the mutation confers a dramatic loss of hERG 1b protein, which was only slightly mitigated by coexpression with hERG 1a (Figure 11A). In 4

![Figure 5](image-url)
separate experiments, no 1b signal could be detected when hERG A8V-1b was expressed in isolation. Coexpression with 1a, which stabilizes the 1b protein, showed the A8V mutation reduced 1b protein levels to 3%, 1%, 6%, and 43%, respectively, in the 4 experiments. Despite the low protein levels, A8V-1b clearly coassembled with stably expressed wild-type 1a subunits to modify the current properties (compare Figure 11B with 11D). Compared with the 1a controls, the mutant reduced total conductance (and, therefore, surface expression levels), as inferred from tail current amplitudes, and variably reduced rectification, as reflected in the ratio of the current amplitude at the end of the test pulse relative to the tail current amplitude. A detailed functional analysis of differences between 1a/1b and 1a/A8V-1b channels will be required to fully understand the biophysical effects of the mutation. Independent of the functional properties, such a dramatic reduction in 1b protein levels in native tissues, where hERG maturation is highly efficient, is expected to decrease the fraction of hERG 1a/1b heteromers and thus reduce the contribution of \( I_{Kr} \) to ventricular repolarization. These findings suggest the hERG 1b A8V mutation predicts a loss of function in patients.

**Discussion**

In this study, we carried out biophysical, pharmacological, computational, and genetic analyses to understand the physiological and pathological role of hERG 1b subunits in heteromeric hERG 1a/1b channels contributing to cardiac \( I_{Kr} \). We used whole-cell voltage clamp at temperatures approximating those in mammalian systems to observe differences in biophysical properties of hERG 1a/1b heteromers compared with the more commonly studied hERG 1a homomers. We found that hERG 1a/1b currents are significantly larger, transferring \( \approx 80\% \) more repolarizing charge because of differences in gating kinetics that reduce rectification and cause the current to peak earlier during the action potential. Apparent activation rates were faster for 1a/1b channels, whereas rates of inactivation over the same voltage range were unchanged. Because of the faster activation at voltages corresponding to the peak of the action potential, there is less rectification and the current amplitude is greater. On repolarization, recovery from inactivation is faster for 1a/1b channels, thus giving rise to an earlier peak (and greater current amplitude) before deactivation ensues. Although deactivation was also faster for 1a/1b channels, current amplitude was
Differences in APD were enhanced in the presence of E-4031, consistent with enhanced drug sensitivity in the absence of the hERG 1b subunit observed experimentally. The importance of hERG 1b in normal physiological function in the human heart is supported by the identification of a 1b-specific mutation, A8V, in a patient referred for LQTS testing but exhibiting no mutations in other known LQTS loci.

The larger amplitude of 1a/1b currents suggest that selective loss of the 1b subunit would give rise to significantly reduced \( I_{Kr} \) in native tissues, and the 1b isoform (and specifically the \( KCNH2 \) 1b exon encoding the unique N-terminal sequences, and/or its promoter) may be a target for mutations causing LQTS. Indeed, a 1b-selective knockout in mouse reduced \( I_{Kr} \) and elicited arrhythmia in a subset of affected animals, consistent with the predictions of our findings in a heterologous system. Because \( I_{Kr} \) contributes much more to repolarization in humans than in adult mice, even a 50% reduction of the 1b subunit in individuals heterozygous for 1b mutations is expected to be deleterious. Our results suggest the reduction in \( I_{Kr} \) current amplitude with the loss of mouse ERG1b may be explained by differences in gating per se, without alterations in ERG1a trafficking, but we cannot rule out a dominant-negative effect of the hERG 1b mutant on \( I_{Kr} \) surface density. Our findings suggest that 1b-specific mutations in humans could reduce \( I_{Kr} \) levels and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.

The observation that hERG 1a/1b channels exhibit lower sensitivity to drug block compared with hERG 1a may have implications for acquired LQTS. If hERG 1a/1b heteromers represent a significant fraction of channels contributing to \( I_{Kr} \), downregulation of 1b would enhance sensitivity to hERG blockers up to 4-fold and increase the risk for arrhythmia by having a predominant population of more drug-sensitive hERG 1a channels rather than the relatively less sensitive hERG 1a/1b channels. As an alternate transcript, expression of hERG 1b is under the control of its own promoter and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.

The observation that hERG 1a/1b channels exhibit lower sensitivity to drug block compared with hERG 1a may have implications for acquired LQTS. If hERG 1a/1b heteromers represent a significant fraction of channels contributing to \( I_{Kr} \), downregulation of 1b would enhance sensitivity to hERG blockers up to 4-fold and increase the risk for arrhythmia by having a predominant population of more drug-sensitive hERG 1a channels rather than the relatively less sensitive hERG 1a/1b channels. As an alternate transcript, expression of hERG 1b is under the control of its own promoter and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.

The observation that hERG 1a/1b channels exhibit lower sensitivity to drug block compared with hERG 1a may have implications for acquired LQTS. If hERG 1a/1b heteromers represent a significant fraction of channels contributing to \( I_{Kr} \), downregulation of 1b would enhance sensitivity to hERG blockers up to 4-fold and increase the risk for arrhythmia by having a predominant population of more drug-sensitive hERG 1a channels rather than the relatively less sensitive hERG 1a/1b channels. As an alternate transcript, expression of hERG 1b is under the control of its own promoter and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.

The observation that hERG 1a/1b channels exhibit lower sensitivity to drug block compared with hERG 1a may have implications for acquired LQTS. If hERG 1a/1b heteromers represent a significant fraction of channels contributing to \( I_{Kr} \), downregulation of 1b would enhance sensitivity to hERG blockers up to 4-fold and increase the risk for arrhythmia by having a predominant population of more drug-sensitive hERG 1a channels rather than the relatively less sensitive hERG 1a/1b channels. As an alternate transcript, expression of hERG 1b is under the control of its own promoter and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.

The observation that hERG 1a/1b channels exhibit lower sensitivity to drug block compared with hERG 1a may have implications for acquired LQTS. If hERG 1a/1b heteromers represent a significant fraction of channels contributing to \( I_{Kr} \), downregulation of 1b would enhance sensitivity to hERG blockers up to 4-fold and increase the risk for arrhythmia by having a predominant population of more drug-sensitive hERG 1a channels rather than the relatively less sensitive hERG 1a/1b channels. As an alternate transcript, expression of hERG 1b is under the control of its own promoter and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.

The observation that hERG 1a/1b channels exhibit lower sensitivity to drug block compared with hERG 1a may have implications for acquired LQTS. If hERG 1a/1b heteromers represent a significant fraction of channels contributing to \( I_{Kr} \), downregulation of 1b would enhance sensitivity to hERG blockers up to 4-fold and increase the risk for arrhythmia by having a predominant population of more drug-sensitive hERG 1a channels rather than the relatively less sensitive hERG 1a/1b channels. As an alternate transcript, expression of hERG 1b is under the control of its own promoter and thus account for previously unmapped cases of inherited, type 2 LQTS or for subclinical reductions of \( I_{Kr} \) that increase susceptibility to hERG blockers and acquired LQTS.
mutations or polymorphisms common to both hERG isoforms.46 Differences in drug sensitivity between hERG 1a and 1a/1b channels provide insights into the mechanism of drug block. If inhibition were attributable only to occlusion on drug binding to hydrophobic residues lining the pore in the open state of the channel,47,48 block should develop more quickly for channels spending more time in the open state. Accordingly, because the larger hERG 1a/1b currents reflect increased occupancy of the open state, one expects block to develop more rapidly. Moreover, the more rapid deactivation of the heteromers might be expected to enhance drug trapping, which contributes to the efficacy of block.29 Instead, drug sensitivity was reduced in hERG 1a/1b channels versus hERG 1a channels, and the development of drug block was slower. This finding suggests that differences in N-terminal structure lead to differences in drug block. Our kinetic model suggests that N-mode gating allows for many more states that can also be bound by drug, thus enhancing efficacy. We can also predict from gating kinetics observed in the current and previous studies that the reduced sensitivity to drug block arises because the 1a/1b heteromer has fewer 1a N termini available to interact with the S4-S5 linker and stabilize inactivation.13 An intimate link exists between inactivation and drug block; in most cases, mutations that disable the inactivation mechanism dramatically reduce inhibition by hERG blockers.49–53 One study provides evidence for the importance of inactivation by demonstrating that the non-
activating hERG relative, bovine Eag, possesses the homologous drug-binding residues in its vestibule but is inhibited by hERG blockers only when inactivation is introduced by mutations at a separate site in the P-region. Our studies support the model that inactivation promotes hERG channel block, demonstrating that allosteric changes caused by structural domains far from the drug-binding site, such as the N terminus, may play an important role.

The differences in hERG 1a and 1a/1b gating kinetics allow us to speculate about the corresponding conformational changes. The similar fold increases in activation and deactivation rates for hERG 1a/1b compared to 1a currents are consistent with the absence of a shift in the \( V_{1/2} \) of the activation curve and suggest that heteromers encounter a lower energy barrier in the transition between the closed and open states. Because the subunits are otherwise identical, this lower energy barrier is attributable to a mechanism involving the N termini of the hERG 1a and 1b channels or a simple reduction in the number of the longer hERG 1a N termini in the heteromer. The N terminus of hERG 1a interacts with or near the S4-S5 linker, which couples movement of the voltage sensor with the opening and closing of the activation gate. Perhaps only 1a N termini interact with the S4-S5 linker, creating a load or stiffness against opening and closing. Although the stoichiometry of hERG 1a/1b heteromers is not known, the heteromer provides fewer 1a N termini, and thus the channel may open and close with less resistance. This model is consistent with the structure of the Kv1.2 S4-S5 linkers, which collectively encircle the residues forming the activation gate within the S6 tetrad.

These are the first studies of hERG 1a/1b channels in mammalian cells recorded at near-physiological tempera-
Previous studies have established differences in temperature sensitivities of hERG 1a gating parameters, such that the overall current profile obtained at lower temperatures differs quite markedly from that recorded at higher temperatures. Such temperature differences are consistent with the much greater reductions in rectification we observe here compared with our previous observations of hERG 1a/1b currents in Xenopus oocytes or those by Bauer and colleagues in clonal pituitary cells, both measured at room temperature. In a recent study of hERG 1a and 1b expressed in CHO cells, gating kinetics measured at room temperature show up to 6-fold increases in deactivation time constants for hERG 1a versus 1a/1b currents. Other gating parameters exhibited relatively minor differences, such as a roughly 50% faster apparent activation rate in hERG 1a/1b but only minor differences in inactivation or recovery from inactivation. Thus, it is critical to consider temperature when extrapolating results of channel function in heterologous expression systems to physiological systems.

How the A8V mutation reduces hERG 1b protein levels is not known. Whether the 1bA8V protein levels are reduced because they oligomerize inefficiently or are inherently unstable, or because the nucleotide mutation leads to transcriptional perturbation or mRNA instability, will require further study to understand. Despite the low levels of A8V protein on Western blots, the mutant subunits do associate with hERG 1a subunits and alter their expression. Because the current properties of hERG 1a/A8V-1b channels were highly variable, we were unable within the scope of this study to precisely characterize the biophysical mutant phenotype. We are currently testing the hypothesis that the mutation reduces overall current levels by associating with hERG 1a subunits and rendering the complex unstable.

There are several unanswered questions regarding the relative disposition of hERG 1a and 1b in native tissues. Although in our previous Western blot analysis we observed robust and roughly equal expression of hERG 1a and 1b subunits in human left ventricle, our more extensive experience in other species shows there is significant variability, the determinants of which we do not currently understand. The stoichiometry is unknown in tissue, although a recent meeting report indicates that assembly in heterologous systems is random, raising the intriguing possibility that stoichiometry may be flexible and established by independent gene expression of the hERG 1a and 1b alternate transcripts. Such regulation may lead to differences in regional, transmural, sex-specific, or developmental expression of the hERG 1b subunit, and thus its importance may be context-specific.
Our findings have implications for both acquired and inherited LQTS. Until now, the primary platform for safety testing drugs in development to prevent acquired LQTS has been HEK-293 cell lines stably expressing solely hERG 1a homomeric channels. Given that different drugs exhibit different pore-binding mechanisms, it will be important to screen a variety of drugs with known torsadogenic potential in cells expressing hERG 1a/1b heteromeric channels that may more closely approximate the composition and functional properties of those underlying native hERG. Our findings also suggest that, in addition to searching for disease mutations in the hERG 1b-specific exon, evaluating the cellular phenotypes of established LQT2-susceptibility mutations and KCNH2 polymorphisms at physiological temperatures in the context of a hERG 1a/1b heteromeric channel rather than the hERG 1a homomeric channel may reveal novel molecular mechanisms for both congenital and drug-induced LQTS.

Acknowledgments

We thank Dr Srinivasan Venkatachalan, Dr Mathew Jones, Dr Eugenia Jones, Sarah Wyna, and other members of the laboratory of G.A.R. for helpful discussions and Rebecca Uelmen and Robert Zinkel for technical assistance.

SOURCES OF FUNDING

This work was supported by NIH grant R01-HL081780 (to G.A.R.); the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (M.J.A.); NIH/National Heart, Lung, and Blood Institute grant R01-HL49054 (to Y.R.); Merit Award R37-Zinkel for technical assistance. G.A.R. for helpful discussions and Rebecca Uelmen and Robert Zinkel for technical assistance.

Disclosure

None.

References


55. Kirchberger NM, Wulfsen I, Schwartz JR, Bauer CK. Effects of TRH on heteromeric rat erg1a/1b K+ channels are dominated by the erg1b subunit. *J Physiol*. 2006;571:27–42.


Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome
Harinath Sale, Jinling Wang, Thomas J. O'Hara, David J. Tester, Pallavi Phartiyal, Jia-Qiang He, Yoram Rudy, Michael J. Ackerman and Gail A. Robertson

Circ Res. 2008;103:e81-e95; originally published online September 5, 2008; doi: 10.1161/CIRCRESAHA.108.185249

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/103/7/e81

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2008/09/05/CIRCRESAHA.108.185249.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
**Detailed Computational Modeling Methods**

Two Markov models, one representing hERG 1a/1b and another representing hERG 1a, were constructed using a previous model for $I_{Kr}$ as a template. Simulations for model validation reproduced the experimental protocols, including temperature (exception: the E-4031 dose response curve was measured at room temperature, but was simulated without adjusting the models which were validated at near-physiological temperature). Matlab and the ode23s integrator (absolute and relative error tolerance set to $10^{-6}$) were used to compute these simulations using a Windows XP desktop computer with a Pentium 4 processor. Parameters were chosen using the interior-reflective Newton method and a least squares objective function to match action potential clamp data for hERG 1a/1b. This was followed by manual refinements to improve correspondence of the models with all of the other data for hERG 1a/1b and to determine the hERG 1a parameters. Equations for the hERG models are given in this online supplement. The hERG models were incorporated into the Fink modified ten Tusscher action potential model in exchange for the native $I_{Kr}$. Action potential simulations were computed using Rush and Larson integration for the cell model (fixed time step = 0.01 ms) and the CVODE integrator for the hERG models (several time steps per 0.01 ms). They were implemented in C++ and run on Linux cluster nodes. All action potential results show the 1000th beat at 1 Hz pacing.
Supplement Figure 1. *Comparison of hERG 1a/1b (blue) and hERG 1a (red) in the action potential without E-4031.* Shown are results from the 1000th paced beat at 1 Hz for the Fink modified3 ten Tusscher action potential model^4. A&B) Action potentials. C) hERG 1a/1b (blue) hERG 1a/1b (blue) and hERG 1a (solid red for normal mode, and dashed red for N-mode). E-4031-blocked state occupancies are zero for hERG 1a/1b and for hERG 1a (not shown) since the drug is not applied in this simulation. APD_{90} (measure of the time elapsed between activation and 90% repolarization) for hERG 1a is 376 ms. This is 38 ms longer than APD_{90} for hERG 1a/1b. The hERG 1a versus hERG 1a/1b prolongation is 30 ms when our models are incorporated into the Priebe and Beuckelmann action potential model^7 (not shown).

Prolongation occurs because N-mode occupancy results in slower activation, and slower closed-state inactivation. N-mode activation is movement from cn3, to cn2, to cn1. This movement is slow compared with c3, to c2, to c1 movement in the normal mode because N-mode
activation/deactivation rates are reduced to 0.35 times the normal mode values. A comparison of early growth and decay for solid versus dashed red lines in panels D-F illustrates this. Closed-state inactivation in the N-mode, which is movement from \( cnl \) to \( in \), is slower than the corresponding normal mode movement from \( cI \) to \( i \). This is because the N-mode transition rate \( \alpha n2 \) is reduced to 0.35 times the corresponding normal mode transition rate \( \alpha 2 \). Thus, recovery current through the open state arrives after a delay in N-mode compared to normal mode. Panels F and H illustrate. In panel F, early \( cnl \) decay is slower than \( cI \) decay. In panel H, decay from normal mode state \( i \) begins at \( t = 60 \) ms while N-mode decay from state \( in \) does not begin until 108 ms later, when \( cnl \) finally finishes emptying into \( in \).

**Supplement Figure 2.** Pause-induced early afterdepolarizations for hERG 1a (red), but not for hERG 1a/1b (blue) in the presence of E-4031. To test for susceptibility to early afterdepolarizations we used the Luo-Rudy midmyocardial ventricular action potential model. Unlike the human-based Fink modified ten Tusscher model and the Priebe and Beuckelmann
model used elsewhere in this study, the guinea pig-based Luo-Rudy model has features that enable the reliable demonstration of early afterdepolarizations under appropriate conditions.\textsuperscript{9,10} This figure shows the Luo-Rudy model paced for 40 beats at a cycle length of 500 ms with hERG 1a or hERG 1a/1b in place of the native I\textsubscript{Kr}. Following these 40 beats (of which the last five are shown), a 1500 ms pause preceded an additional single paced beat. [E-4031] was set to 55 nM, the minimum concentration needed to cause an early afterdepolarization. The formation of early afterdepolarizations for hERG 1a but not for hERG 1a/1b demonstrates a connection between the altered channel kinetics of hERG 1a and the clinical appearance of torsades de pointes arrhythmia in the presence of hERG blocking drugs following a pause\textsuperscript{11}. 
Model Equations.

hERG 1a/1b model transition rates (ms⁻¹)

\[ \alpha = 0.03552 \times \exp \left[ 1.812 \times \frac{VF}{RT} \right] \]

\[ \beta = 1.807e - 3 \times \exp \left[ -1.913 \times \frac{VF}{RT} \right] \]

\[ \alpha_1 = 4.340 \]
\[ \beta_1 = 0.5409 \]

\[ \alpha_2 = 0.02620 \times \exp \left[ 1.241 \times \frac{VF}{RT} \right] \]

\[ \beta_2 = 3.300e - 3 \times \exp \left[ -0.9571 \times \frac{VF}{RT} \right] \]

\[ \alpha_i = 0.1139 \times \exp \left[ -0.4898 \times \frac{VF}{RT} \right] \times \left[ \frac{4.5}{K^+} \right] \]

\[ \beta_i = 0.1254 \times \exp \left[ 0.3781 \times \frac{VF}{RT} \right] \times \left( \frac{4.5}{K^+} \right)^3 \]

\[ \mu = \frac{\alpha_i \times \beta_2}{\beta_i} \]

\[ \text{ON} = [E4031] \times 2.0e3, \text{ with } [\text{E-4031}] \text{ in mol/L} \]
\[ \text{OFF} = 5.0e - 6 \]

10 coupled ordinary differential equations

\[ \frac{dc_3}{dt} = c_2 \times \beta - c_3 \times \alpha \]

\[ \frac{dc_2}{dt} = c_3 \times \alpha + c_1 \times \beta_1 - c_2 \times (\beta + \alpha_1) \]

\[ \frac{dc_1}{dt} = c_2 \times \alpha_1 + c_1 \times \beta_2 + i \times \mu - c_1 \times (\beta_1 + 2 \times \alpha_2) \]

\[ \frac{do}{dt} = c_1 \times \alpha_2 + i \times \alpha_i + b \times \text{OFF} - o \times (\beta_2 + \beta_i + \text{ON}) \]

\[ \frac{di}{dt} = c_1 \times \alpha_2 + o \times \beta_i - i \times (\mu + \alpha_i) \]

\[ \frac{dcb_3}{dt} = cb_2 \times \beta - cb_3 \times \alpha \]
\[
\begin{align*}
\frac{dcb_2}{dt} &= cb3* \alpha + cb1* \beta_1 - cb2* (\beta + \alpha_1) \\
\frac{dcb_1}{dt} &= cb2* \alpha_1 + b* \beta_2 + ib* \mu - cb1* (\beta_1 + 2* \alpha_2) \\
\frac{db}{dt} &= cb1* \alpha_2 + ib* \alpha_i + o* ON - b* (\beta_2 + \beta_i + OFF) \\
\frac{dib}{dt} &= cb1* \alpha_2 + b* \beta_i - ib* (\mu + \alpha_i)
\end{align*}
\]

Initial Conditions

\[
c_3 = 1 \\
c_2 = c_1 = o = i = c_3 = cb_2 = cb_1 = b = ib = 0
\]

Calculation of Current

\[
\begin{align*}
\bar{\alpha}_{\text{hERG}} &= 0.0048 \text{ mS}, \text{ Fink modified}, \text{ ten Tusscher}^d \\
\bar{\alpha}_{\text{hERG}} &= 0.015 \text{ mS}, \text{ Priebe and Buekelmann}^7 \\
\bar{\alpha}_{\text{hERG}} &= 0.02614 \text{ mS}, \text{ Luo and Rudy}^8
\end{align*}
\]

\[
E_K = \frac{RT}{F} \ln \left( \frac{[K^+]_o}{[K^+]_i} \right)
\]

\[
I_{\text{hERG,1a/ib}} = \bar{\alpha}_{\text{hERG}} \sqrt{[K^+]_o/5.4*o*(V - E_K)}
\]

hERG 1a model transition rates (ms\(^{-1}\))

\[
\begin{align*}
\alpha &= 0.03552* \exp \left[1.812* \frac{VF}{RT} \right] \\
\beta &= 1.807e - 3* \exp \left[-1.913* \frac{VF}{RT} \right] \\
\alpha_1 &= 4.340 \\
\beta_1 &= 0.5409 \\
\alpha_2 &= 0.02620* \exp \left[1.241* \frac{VF}{RT} \right] \\
\beta_2 &= 3.300e - 3* \exp \left[-0.9571* \frac{VF}{RT} \right]
\end{align*}
\]

\[I_{\text{hERG,1a/ib}} = \bar{\alpha}_{\text{hERG}} \sqrt{[K^+]_o/5.4*o*(V - E_K)}
\]
\[ \alpha_i = 0.1139 \times \exp \left( -0.4898 \times \frac{VF}{RT} \right) \times \frac{4.5}{K^+} \]

\[ \beta_i = 0.1254 \times \exp \left( 0.3781 \times \frac{VF}{RT} \right) \times \left( \frac{4.5}{K^+} \right)^3 \]

\[ \mu = \frac{\alpha_i \times \beta_2}{\beta_i} \]

\[ \alpha_n = 0.35 \times \alpha \]

\[ \beta_n = 0.35 \times \beta \]

\[ \alpha_{n1} = 0.35 \times \alpha_1 \]

\[ \beta_{n1} = 0.35 \times \beta_1 \]

\[ \alpha_{n2} = 0.35 \times \alpha_2 \]

\[ \beta_{n2} = 0.35 \times \beta_2 \]

\[ \alpha_{ni} = 0.4 \times \alpha_i \]

\[ \beta_{ni} = 1.2 \times \beta_i \]

\[ \mu_n = \frac{\alpha_{ni} \times \beta_{n2}}{\beta_{ni}} \]

\[ ON = [E4031] \times 2.0e3 \text{, with \ } [E-4031] \text{ in mol/L} \]

\[ OFF = 5.0e-6 \]

\[ \theta = 5.0 \]

\[ \rho = 2.0 \]

\[ \kappa = ON \times \theta \]

\[ \lambda = ON \times \rho \]

\[ \delta = OFF \times \theta \]

\[ \nu = OFF \times \rho \]

20 coupled ordinary differential equations

\[ \frac{dc3}{dt} = c2 \times \beta - c3 \times \alpha \]

\[ \frac{dc2}{dt} = c3 \times \alpha + c1 \times \beta_1 - c2 \times (\beta_1 + \alpha_1) \]

\[ \frac{dc1}{dt} = c2 \times \alpha_1 + o \times \beta_2 + i \times \mu - c1 \times (\beta_1 + 2 \times \alpha_2) \]

\[ \frac{do}{dt} = c1 \times \alpha_2 + i \times \alpha_i + on \times \rho + b \times OFF + nb \times v - o \times (\beta_2 + \beta_i + \theta + ON + \kappa) \]

\[ \frac{di}{dt} = c1 \times \alpha_2 + o \times \beta_i - i \times (\mu + \alpha_i) \]

\[ \frac{dcn3}{dt} = cn2 \times \beta_n - cn3 \times \alpha_n \]
\[
\frac{dcn_2}{dt} = cn3*\alpha n + cn1*\beta n1 - cn2*(\beta n + \alpha n1)
\]
\[
\frac{dcn_1}{dt} = cn2*\alpha n1 + on*\beta n2 + in*\mu n - cn1*(\beta n1 + 2*\alpha n2)
\]
\[
\frac{don}{dt} = cn1*\alpha n2 + in*\alpha n1 + o*\theta + b*\delta + nb*OFF - on* (\beta n2 + \beta n1 + \rho + \lambda + ON)
\]
\[
\frac{din}{dt} = cn1*\alpha n2 + on*\beta ni - in* (\mu n + \alpha n1)
\]
\[
\frac{dcb_3}{dt} = cb2*\beta - cb3*\alpha
\]
\[
\frac{dcb_2}{dt} = cb3*\alpha + cb1*\beta 1 - cb2*(\beta + \alpha 1)
\]
\[
\frac{dcb_1}{dt} = cb2*\alpha 1 + b*\beta 2 + ib*\mu - cb1*(\beta 1 + 2*\alpha 2)
\]
\[
\frac{db}{dt} = cb1*\alpha 2 + ib*\alpha i + o*ON + on*\lambda + nb*\rho - b*(\beta 2 + \beta i + OFF + \delta + \theta)
\]
\[
\frac{dib}{dt} = cb1*\alpha 2 + b*\beta i - ib*(\mu + \alpha i)
\]
\[
\frac{dcnb_3}{dt} = cnb2*\beta n - cnb3*\alpha n
\]
\[
\frac{dcnb_2}{dt} = cnb3*\alpha n + cnb1*\beta n1 - cnb2*(\beta n + \alpha n1)
\]
\[
\frac{dcnb_1}{dt} = cnb2*\alpha n1 + nb*\beta n2 + inb*\mu n - cnb1*(\beta n1 + 2*\alpha n2)
\]
\[
\frac{dnb}{dt} = cnb1*\alpha n2 + inb*\alpha n1 + o*\kappa + on*ON + b*\theta - nb*(\beta n2 + \beta n1 + v + OFF + \rho)
\]
\[
\frac{dinb}{dt} = cnb1*\alpha n2 + nb*\beta ni - inb*(\mu n + \alpha n1)
\]

Initial Conditions

\[
c3 = \frac{\rho}{\rho + \theta} = 0.285714286
\]
\[
c2 = c1 = o = i = cb3 = cb2 = cb1 = b = ib = 0
\]
\[
cn3 = \frac{\theta}{\rho + \theta} = 0.714285714
\]
\[
cn2 = cn1 = on = in = cnb3 = cnb2 = cnb1 = nb = inb = 0
\]

Calculation of Current

\[\bar{G}_{\text{HERG}} = 0.0048 \text{ mS, Fink modified}^3, \text{ ten Tusscher}^4\]
$\bar{G}_{\text{hERG}} = 0.015 \text{ mS, Priebe and Bueckelmann}^7$

$\bar{G}_{\text{hERG}} = 0.02614 \text{ mS, Luo and Rudy}^8$

$$E_K = \frac{RT}{F} \ln \left( \frac{[K^+]_o}{[K^+]_e} \right)$$

$$I_{i\text{hERG}} = \bar{G}_{\text{hERG}} * \sqrt{[K^+]_o / \text{5.4} * (o + on) * (V - E_K)}$$


